CLAIMS

We claim:

1. A method of treating an inflammatory disease or inflammatory disorder in a person in need thereof comprising administering an anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 and at least one disease modifying anti-rheumatic drug to the person in a therapeutically effective amount.

2. The method of claim 1 wherein the disease modifying anti-rheumatic drug is methotrexate.

3. The method of claim 1 wherein the disease modifying anti-rheumatic drug is sulfasalazine.

4. A method of treating arthritis in a person in need thereof comprising administering an anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 and at least one disease modifying anti-rheumatic drug to the person in a therapeutically effective amount.

5. The method of claim 4 wherein the disease modifying anti-rheumatic drug is methotrexate.

6. The method of claim 4 wherein the disease modifying anti-rheumatic drug is sulfasalazine.

7. A method of treating rheumatoid arthritis in a person in need thereof comprising administering an anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 and at least one disease modifying anti-rheumatic drug to the person in a therapeutically effective amount.

8. The method of claim 7 wherein the disease modifying anti-rheumatic drug is methotrexate.

9. The method of claim 7 wherein the disease modifying anti-rheumatic drug is sulfasalazine.

10. A method of treating inflammatory disease or disorder in a person in need thereof comprising co-administering an anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 and at least one disease modifying anti-rheumatic drug to the person in a therapeutically effective amount.

11. The method of claim 10 wherein the disease modifying anti-rheumatic drug is methotrexate.

12. The method of claim 10 wherein the disease modifying anti-rheumatic drug is sulfasalazine.

13. A method of treating arthritis in a person in need thereof comprising co-administering an anti-tumor necrosis factor antibody Fab' fragment CDP870 and at least one disease modifying anti-rheumatic drug to the individual in a therapeutically effective amount.

14. The method of claim 13 wherein the disease modifying anti-rheumatic drug is methotrexate.

15. The method of claim 13 wherein the disease modifying anti-rheumatic drug is sulfasalazine.

16. A method of treating rheumatoid arthritis in a person in need thereof comprising co-administering an anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 and at least one disease modifying anti-rheumatic drug to the person in a therapeutically effective amount.

17. The method of claim 16 wherein the disease modifying anti-rheumatic drug is methotrexate.

18. The method of claim 16 wherein the disease modifying anti-rheumatic drug is sulfasalazine.

19. A method of treating an inflammatory disease or disorder in a person in need thereof comprising sequentially administering an anti-tumor necrosis factor alpha antibody and sulfasalazine to the person in a therapeutically effective amount.

20. The method of claim 19 wherein the inflammatory disease is arthritis.

21. The method of claim 19 wherein the inflammatory disease is rheumatoid arthritis.

22. A method of treating arthritis in a person in need thereof comprising sequentially administering an anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 and at least one disease modifying anti-rheumatic drug to the person in a therapeutically effective amount.

23. The method of claim 22 wherein the disease modifying anti-rheumatic drug is methotrexate.

24. The method of claim 22 wherein the disease modifying anti-rheumatic drug is sulfasalazine.

25. A method of treating rheumatoid arthritis in a person in need thereof comprising sequentially administering an anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 and at least one disease modifying anti-rheumatic drug to the person in a therapeutically effective amount.

26. The method of claim 25 wherein the disease modifying anti-rheumatic drug is methotrexate.

27. The method of claim 25 wherein the disease modifying anti-rheumatic drug is sulfasalazine.

28. A method for treatment, prevention or inhibition of inflammation or inflammation-related disorder in a person in need of such treatment, prevention or inhibition, the comprising treating the person with an anti-tumor necrosis factor alpha antibody Fab' fragment CDP 870 and a disease modifying anti-rheumatic drug in a therapeutically effective amount.

29. The method of claim 28 wherein the disease modifying anti-rheumatic drug is methotrexate.

30. The method of claim 28 wherein the disease modifying anti-rheumatic drug is sulfasalazine.

31. A method for treatment, prevention or inhibition of rheumatory arthritis or a related disorder, or inflammation-associated with rheumatory arthritis in a person in need of such treatment, prevention or inhibition, the comprising the step of treating the person with an anti-tumor necrosis factor alpha antibody Fab' fragment CDP 870 and a disease modifying anti-rheumatic drug in a therapeutically effective amount.

32. The method of claim 31 wherein the disease modifying anti-rheumatic drug is methotrexate.

33. The method of claim 31 wherein the disease modifying anti-rheumatic drug is sulfasalazine.

34. A composition for the treatment, prevention, or inhibition of inflammation, or inflammation-associated disorder comprising an anti-tumor necrosis factor alpha antibody Fab' fragment CDP 870 and a disease modifying anti-rheumatic drug.

35. The composition of claim 34 wherein the disease modifying anti-rheumatic drug is methotrexate.

36. The composition of claim 34 wherein the disease modifying anti-rheumatic drug is sulfasalazine.

37. A composition for the treatment, prevention or inhibition or pain of rheumatoid arthritis or rheumatoid arthritis associated disorder comprising an anti-tumor necrosis factor alpha antibody Fab' fragment CDP 870 and a disease modifying anti-rheumatic drug.

38. The composition of claim 37 wherein the disease modifying anti-rheumatic drug is methotrexate.

39. The composition of claim 37 wherein the disease modifying anti-rheumatic drug is sulfasalazine.

40. A kit that is suitable for use in the treatment, prevention or inhibition of pain, inflammation or inflammation-associated disorder comprising a first dosage form of an anti-tumor necrosis factor alpha antibody Fab' fragment CDP 870 and a second dosage form of a disease modifying anti-rheumatic drug, said first dosage form and said second dosage form provided in quantities which comprise a therapeutically effect amount of the compounds for the treatment, prevention or inhibition of cardiovascular disease or disorder.

41. The kit of claim 40 wherein the disease modifying anti-rheumatic drug is methotrexate.

42. The kit of claim 42 wherein the disease modifying anti-rheumatic drug is sulfasalazine.

43. A kit that is suitable for use in the treatment, prevention or inhibition of rheumatoid arthritis or a rheumatoid arthritis-associated disorder comprising a first dosage form of an anti-tumor necrosis factor alpha antibody Fab' fragment CDP 870 and a second dosage form of a disease modifying anti-rheumatic drug, said first dosage form and said second dosage form provided in quantities which comprise a therapeutically effect amount of the compounds for the treatment, prevention or inhibition of cardiovascular disease or disorder.

44. The kit of claim 43 wherein the disease modifying anti-rheumatic drug is methotrexate.

45. The kit of claim 43 wherein the disease modifying anti-rheumatic drug is sulfasalazine.

46. A kit that is suitable for use in the treatment, prevention or inhibition of pain, inflammation or inflammation-associated disorder comprising a dosage form of an anti-tumor necrosis factor alpha antibody Fab' fragment CDP 870 and a disease modifying anti-rheumatic drug wherein said dosage form is provided in quantities which comprise a therapeutically effect amount of the compounds for the treatment, prevention or inhibition of cardiovascular disease or disorder.

47. The kit of claim 46 wherein the disease modifying anti-rheumatic drug is methotrexate.

48. The kit of claim 46 wherein the disease modifying anti-rheumatic drug is sulfasalazine.

49. A method of treating an inflammatory disease or inflammatory disorder in a person in need thereof comprising:

(a) preparing a therapeutic composition comprising a therapeutically effective amount of an anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 and at lease one disease modifying anti-rheumatic drug; and

(b) administering in a repetitive dosing regimen the therapeutic composition to the person.

50. The method of claim 49 wherein the repetitive dosing regimen of the anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 is about once every four weeks.

51. The method of claim 50 wherein the therapeutic effective amount of the anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 is about 200 mg to about 800 mg.

52. The method of claim 50 wherein the therapeutic effective amount of the anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 is about 400 mg.

53. The method of claim 49 wherein the disease modifying anti-rheumatic is methotrexate.

54. The method of claim 53 wherein the repetitive dosing regimen of the methotrexate is about once every week.

55. The method of claim 54 wherein the therapeutic effective amount of methotrexate is about 2.5 mg to about 50 mg.

56. The method of claim 54 wherein the therapeutic effective amount of the methotrexate is about 7.5 mg to about 15 mg.

57. The method of claim 49 wherein the disease modifying anti-rheumatic is sulfasalazine.

58. The method of claim 57 wherein the repetitive dosing regimen of the sulfasalazine is about once every day.

59. The method of claim 58 wherein the therapeutic effective amount of sulfasalazine is about 0.5 g to about 3 g.

60. The method of claim 58 wherein the therapeutic effective amount of the methotrexate is about 2 g to about 3 g.

61. A method of modulating an inflammatory disease or inflammatory disorder in a person in need thereof comprising administering an anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 and at least one disease modifying anti-rheumatic drug to the person in a therapeutically effective amount.

62. The method of claim 61 wherein the disease modifying anti-rheumatic drug is methotrexate.

63. The method of claim 61 wherein the disease modifying anti-rheumatic drug is sulfasalazine.

64. A method of modulating arthritis in a person in need thereof comprising administering an anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 and at least one disease modifying anti-rheumatic drug to the person in a therapeutically effective amount.

65. The method of claim 64 wherein the disease modifying anti-rheumatic drug is methotrexate.

66. The method of claim 64 wherein the disease modifying anti-rheumatic drug is sulfasalazine.

67. A method of modulating rheumatoid arthritis in a person in need thereof comprising administering an anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 and at least one disease modifying anti-rheumatic drug to the person in a therapeutically effective amount.

68. The method of claim 67 wherein the disease modifying anti-rheumatic drug is methotrexate.

69. The method of claim 67 wherein the disease modifying anti-rheumatic drug is sulfasalazine.

70. A method of modulating inflammatory disease or disorder in a person in need thereof comprising co-administering an anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 and at least one disease modifying anti-rheumatic drug to the person in a therapeutically effective amount.

71. The method of claim 70 wherein the disease modifying anti-rheumatic drug is methotrexate.

72. The method of claim 70 wherein the disease modifying anti-rheumatic drug is sulfasalazine.

73. A method of modulating arthritis in a person in need thereof comprising co-administering an anti-tumor necrosis factor antibody Fab' fragment CDP870 and at least one disease modifying anti-rheumatic drug to the individual in a therapeutically effective amount.

74. The method of claim 73 wherein the disease modifying anti-rheumatic drug is methotrexate.

75. The method of claim 73 wherein the disease modifying anti-rheumatic drug is sulfasalazine.

76. A method of modulating rheumatoid arthritis in a person in need thereof comprising co-administering an anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 and at least one disease modifying anti-rheumatic drug to the person in a therapeutically effective amount.

77. The method of claim 76 wherein the disease modifying anti-rheumatic drug is methotrexate.

78. The method of claim 76 wherein the disease modifying anti-rheumatic drug is sulfasalazine.

79. A method of modulating an inflammatory disease or disorder in a person in need thereof comprising sequentially administering an anti-tumor necrosis factor alpha antibody and sulfasalazine to the person in a therapeutically effective amount.

80. The method of claim 79 wherein the inflammatory disease is arthritis.

81. The method of claim 79 wherein the inflammatory disease is rheumatoid arthritis.

82. A method of modulating arthritis in a person in need thereof comprising sequentially administering an anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 and at least one disease modifying anti-rheumatic drug to the person in a therapeutically effective amount.

83. The method of claim 82 wherein the disease modifying anti-rheumatic drug is methotrexate.

84. The method of claim 82 wherein the disease modifying anti-rheumatic drug is sulfasalazine.

85. A method of modulating rheumatoid arthritis in a person in need thereof comprising sequentially administering an anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 and at least one disease modifying anti-rheumatic drug to the person in a therapeutically effective amount.

86. The method of claim 85 wherein the disease modifying anti-rheumatic drug is methotrexate.

87. The method of claim 85 wherein the disease modifying anti-rheumatic drug is sulfasalazine.